Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.67 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.60 |
| ▸ | PRKCG | P05129 | 2/20 | 0.60 |
| ▸ | PRKCB | P05771 | 2/20 | 0.60 |
| ▸ | PRKCA | P17252 | 2/20 | 0.60 |
| ▸ | PRKCH | P24723 | 2/20 | 0.60 |
| ▸ | PRKCI | P41743 | 2/20 | 0.60 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.60 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.60 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.60 |
| ▸ | AKT1 | P31749 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30512149 | 1.00 | LPAR1 (0.67) | LPAR1LPAR3PRKD3PRKCGPRKCB | |
| SCHEMBL30699444 | 1.00 | LPAR1 (0.67) | LPAR1LPAR3PRKD3PRKCGPRKCB | |
| SCHEMBL28623629 | 1.00 | LPAR1 (0.67) | LPAR1LPAR3PRKD3PRKCGPRKCB | |
| SCHEMBL31282060 | 1.00 | LPAR1 (0.67) | LPAR1LPAR3PRKD3PRKCGPRKCB | |
| SCHEMBL28700507 | 1.00 | LPAR1 (0.67) | LPAR1LPAR3PRKD3PRKCGPRKCB | |
| SCHEMBL14447803 | 1.00 | LPAR1 (0.67) | LPAR1LPAR3PRKD3PRKCGPRKCB | |
| SCHEMBL19405591 | 1.00 | LPAR1 (0.67) | LPAR1LPAR3PRKD3PRKCGPRKCB | |
| SCHEMBL20851913 | 1.00 | LPAR1 (0.67) | LPAR1LPAR3PRKD3PRKCGPRKCB | |
| SCHEMBL22023007 | 1.00 | LPAR1 (0.67) | LPAR1LPAR3PRKD3PRKCGPRKCB | |
| SCHEMBL28825839 | 1.00 | LPAR1 (0.67) | LPAR1LPAR3PRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515598-A | Pharmaceutical composition of niclosamide | 德克萨斯大学系统董事会 | 2022-12-23 | — | — | CN | claimed |
| CN-105431139-B | For carrying out the stereospecificity lipid of local treatment with the stimulation-sensibility nano-carrier system recycled for a long time | 特默佐梅有限公司 | 2019-10-01 | — | — | CN | claimed |
| CN-117946201-A | Lipid compounds and lipid nanoparticle compositions | 仁景(苏州)生物科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-11633365-B2 | Nucleic acid-containing lipid nanoparticle | KYOWA KIRIN CO., LTD. (JP) | 2023-04-25 | — | — | US | disclosed |
| CN-115515598-A | Pharmaceutical composition of niclosamide | 德克萨斯大学系统董事会 | 2022-12-23 | — | — | CN | disclosed |
| CN-113603763-A | Fat body and application thereof in detection of ATGL enzyme activity | 中国科学院生物物理研究所 | 2021-11-05 | — | — | CN | disclosed |
| CN-111057136-B | Fat body and application thereof in evaluating interaction between protein to be detected and fat droplets | 中国科学院生物物理研究所 | 2021-09-28 | — | — | CN | disclosed |
| CN-113015540-A | Methods and compositions for treating cancer using MRNA therapeutics | 莫得纳特斯公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-112546201-A | Application of artificial lipoprotein particle apoA-IV fat body in treatment and/or prevention of diabetes | 中国科学院生物物理研究所 | 2021-03-26 | — | — | CN | disclosed |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | KYOWA KIRIN CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
| CN-111315359-A | Method for preparing lipid nanoparticles | 摩登纳特斯有限公司 | 2020-06-19 | — | — | CN | disclosed |
| EP-3662913-A1 | NUCLEIC-ACID-CONTAINING LIPID NANOPARTICLES | Kyowa Kirin Co., Ltd. (JP) | 2020-06-10 | — | — | EP | disclosed |
| CN-111057136-A | Fat body and application thereof in evaluating interaction between protein to be detected and fat droplets | 中国科学院生物物理研究所 | 2020-04-24 | — | — | CN | disclosed |
| CN-110403917-A | A kind of artificial excretion body, preparation method and application | UNIV GUANGZHOU MEDICAL | 2019-11-05 | — | — | CN | disclosed |
| CN-1089470-A | Be used for granule of NMR (Nuclear Magnetic Resonance)-imaging and preparation method thereof | SINT SA (CH) | 1994-07-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633365-B2 | Nucleic acid-containing lipid nanoparticle | LIPA, LIPC, PNLIP | LPAR1 102/4885LPAR3 85/4885PRKD3 2607/4885 |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | LIPA, LIPC, PNLIP | LPAR1 102/4885LPAR3 85/4885PRKD3 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.